Development of advanced humanized models: The future of pre-clinical testing of immune therapies?
Abstract
Immune therapies have advanced therapeutic outcomes in a number of cancers. Future advancement of these therapies largely depends on the development of reliable immunocompetent pre-clinical models that mimic human disease.1 Humanized patient-derived xenograft (PDX) models have become essential for evaluating new immune therapies for clinical translation, yet their limitations restrict their use as models for advanced therapeutics.2 Steinkamp et al. describe a humanized mouse model addressing these limitations, supporting clinical translation of a silicified cancer cell vaccine presenting a Toll-like receptor antagonist.
Fields of Study & Subjects
Immunotherapy and Immune Responses
Cancer Immunotherapy and Biomarkers
T-cell and B-cell Immunology
Publication details
- Journal / source
- Molecular Therapy Oncology
- Volume
- 34
- Issue
- 1
- Pages
- 201170–201170
- Publication date
- 1 March 2026
- Language
- EN